Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status:
Completed
Trial end date:
2020-06-16
Target enrollment:
Participant gender:
Summary
To evaluate the long-term safety and tolerability of subcutaneous (SC) administration of
TEV-48125 (at 225 mg once monthly [except for a loading dose of 675 mg for CM patients] or at
675 mg every 3 months) for the preventive treatment of Chronic Migraine and Episodic Migraine
patients